ADx
Pre-clinical- Indications
- Alzheimer's disease
Company intelligence / Profile preview
Alzeca Biosciences has demonstrated in preclinical studies that its proprietary ADx nanoparticle imaging agent can cross the blood-brain barrier and bind specifically to amyloid plaques. This enables high-resolution detection of early-stage Alzheimer’s pathology using standard MRI equipment. Preliminary toxicity studies have been successful, with plans for human clinical trials announced but not confirmed as started by latest public information.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alzeca Biosciences.